Schizophrenia Research
Volume 86, Issue 1 , Pages 99-109 , September 2006

Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era

  • Anirban Basu

      Affiliations

    • Section of General Internal Medicine, Department of Medicine, Center for Health and the Social Sciences, University of Chicago, 5841 S. Maryland Ave, MC-2007, Chicago IL 60637, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 773 834 1796; fax: +1 773 834 2238.
    • ,
  • Herbert Y. Meltzer

      Affiliations

    • Departments of Psychiatry and Pharmacology, Vanderbilt University, Nashville, TN, United States

Received 6 January 2006 ,Revised 18 April 2006 ,Accepted 21 April 2006.

References 

  1. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210–1214
  2. American Diabetes Association . Economic costs of diabetes in US in 2002. Diabetes Care. 2003;26(3):917–932
  3. American Diabetes Association , American Psychiatric Association , American Association of Clinical Endocrinologists , North American Association for the Study of Obesity . Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry. 2004;65(2):267–272
  4. Bagnall AM, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol. Assess. 2003;7(13):1–193
  5. Brown S. Excess mortality in schizophrenia: a meta-analysis. Br. J. Psychiatry. 1997;171:502–508
  6. Bushe C, Holt R. Prevalence of diabetes and glucose intolerance in patients with schizophrenia. Br. J. Psychiatry. 2004;184(Suppl 47):67–71
  7. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes melittus and antipsychotic treatment in the United States. J. Clin. Epidemiol. 2003;56:164–170
  8. Duggan M. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. J. Health Econ. 2005;24(1):1–31
  9. Dynes JB. Diabetes in schizophrenia and diabetes in nonpsychotic medical patients. Dis. Nerv. Syst. 1969;30:341–344
  10. Ertugrul A, Meltzer HY. Antipsychotic drugs in bipolar disorder. Int. J. Neuropsychopharmacol. 2003;6(3):277–284
  11. Felker B, Yazel JJ, Short D. Mortality and medical comorbidity among psychiatric patients: a review. Psych. Serv. 1996;47:1356–1363
  12. Geddes J. Generating evidence to inform policy and practice: the example of the second generation “atypical” antipsychotics. Schizophr. Bull. 2003;29(1):105–114
  13. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J. Clin. Psychiatry. 2002;63(10):920–930
  14. Gianfrancesco F, White R, Wang RH, Nasrallah HA. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J. Clin. Psychopharmacol. 2003;23(4):328–335
  15. Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, Copeland PM, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J. Clin. Psychiatry. 2005;66(2):183–194
  16. Gutiérrez F, Masiá M, Rodríguez JC, Mirete C, Soldán B, Padilla S, et al. Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome. Eur. J. Clin. Microbiol. Infect. Dis. 2005;24(6):377–383
  17. Hebert PL, Geis LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM. Identifying persons with diabetes using Medicare claims data. Am. J. Med. Qual. 1999;14(6):270–277
  18. Holland P. Statistics and causal inference. J. Am. Stat. Assoc. 1986;81:945–970
  19. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr. Res. 2004;71(2–3):195–212
  20. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22(7):841–852
  21. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am. J. Med. 2001;111(9):716–723
  22. Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003;23(6):735–744
  23. Koller E, Weber J, Doraiswamy PM, Schneider BS. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J. Clin. Psychiatry. 2004;65(6):857–863
  24. Kong SX, Hatoum HT, Zhao SZ, Agrawal NM, Geis SG. Prevalence and cost of hospitalization for gastrointestinal complications related to peptic ulcers with bleeding or perforation: comparison of two national databases. Am. J. Man. Care. 1998;4(3):399–409
  25. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br. Med. J. 2002;325(3):243–245
  26. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am. J. Psychiatry. 2004;161:1709–1711
  27. Lieberman JA, Stroup TS, McEvoy JP Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005;353(12):1209–1223
  28. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension. Arch. Gen. Psychiatry. 2001;58:1172–1176
  29. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923
  30. McEvoy JP, Meyer JM, Nasrallah HA, Goff DC, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial and Comparison with National Estimates from NHANES III. Schizophr. Res. 2005;80:19–32
  31. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus and lipid abnormalities. Can. J. Psychiatry. 2001;46:273–281
  32. McKee HA, D'Arcy PF, Wilson PJ. Diabetes and schizophrenia — A preliminary study. J. Clin. Hosp. Pharm. 1986;11:297–299
  33. Meltzer HY. The metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?. Int. J. Neuropsychopharmacol. 2005;8(2):153–156
  34. Mental Health: A Report of the Surgeon General - Surgeon General's Office. Table 2–6. 1997. Available at : http://www.surgeongeneral.gov/library/mentalhealth/toc.html. Accessed August 31, 2005.
  35. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J. Clin. Psychiatry. 2001;62:27–34(discussion 40–21)
  36. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 2004;70:1–17
  37. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Compr. Psychiatry. 1996;37:68–73
  38. National Center for Health Statistics. United States Life Tables, 2002. National Vital Statistics Report 2004; 53(6):39. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr53/nvsr53_06.pdf. Accessed August 31, 2005.
  39. Newcomer J. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1–93
  40. Ollendorf DA, Joyce AT, Rucker M. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. Medscape Gen. Med. 2004;6(1):
  41. Osby U, Correia N, Brandt L, Ekbom A, Sparen Par. Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study. BMJ. 2000;321:483–484
  42. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002;35:367–372
  43. Peet M. Diet, diabetes and schizophrenia: review and hypothesis. Br. J. Clin. Psychol. 2004;184(supp. 47):s102–s105
  44. Rubin D. Estimating causal effects of treatment in randomized and non-randomized studies. J. Educ. Psychol. 1974;66:688–701
  45. Schiller, J. S., Martinez, M., Barnes, P., 2006. Early release of selected estimates based on data from the January–September 2005 National Health Interview Survey. National Center for Health Statistics. http://www.cdc.gov/nchs/nhis.htm.
  46. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry. 2002;159:561–566
  47. Sumiyoshi T, Roy A, Anil AE, Jayathilake K, Ertugrul A, Meltzer HY. A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine. J. Clin. Psychopharmacol. 2004;24(3):345–348
  48. Sumiyoshi T, Roy A, Jayathilake K, Meltzer HY. The effect of hypertension and obesity on the development of diabetes mellitus in patients treated with atypical antipsychotic drugs. J. Clin. Psychopharmacol. 2004;24(4):452–454
  49. Tenback, D.E., van Harten, P.N., Slooff, C.J., Belger, M.A., van Os, J., SOHO Study Group. 2005. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study 66(9):1130–3.
  50. Van Brunt DL, Gibson J, Ramsey JL, Obenchain R. Outpatient use of major antipsychotic drugs in ambulatory care settings in the United States, 1997–2000. Medscape Gen. Med. 2003;5(3):
  51. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005;8(3):457–472

PII: S0920-9964(06)00201-5

doi: 10.1016/j.schres.2006.04.014

Schizophrenia Research
Volume 86, Issue 1 , Pages 99-109 , September 2006

Article Tools

* Image Usage & Resolution